VL-PX10

Phase 1Small molecule

VVitti Labs, LLC

VL-PX10 is one of 14 small molecule programs targeting Premature ovarian insufficiency. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Premature Ovarian InsufficiencyActive, not recruiting

Premature Ovarian InsufficiencyPhase 1

Active, not recruiting

Competition

Competitive Landscape

23 competitors in Premature Ovarian Insufficiency

#DrugCompanyPhaseTrials

Estrace

Novo Nordisk

Approved

—2

Zoladex

TTerSera Therapeutics LLC

Activella

1 4

Prometrium

Ferring

Phase 3

1 5

Neupogen

EEastern Cooperative Oncology Group

Phase 3

1 6

Rituxan

Roche

Phase 2

1 7

Depo-Provera

NEUPOGEN

1 9

Combined Oral Contraceptives

VViatris Innovation GmbH

Phase 3

1 10

Platelet Rich Plasma

ZZagazig University

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Premature ovarian insufficiency1 trial

A Proof of Concept Study to Evaluate Exosomes From Human Mesenchymal Stem Cells in Women With Premature Ovarian Insufficiency (POI)

Suspended·VVitti Labs, LLC·Phase 1·NCT06072794·9 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for VL-PX10. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — VL-PX10 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for VL-PX10. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Vitti Labs, LLC company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: VVitti Labs, LLC

VL-PX10

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Premature ovarian insufficiency1 trial

References

Drug Info

Quick Facts

Related News